OHARA Pharmaceutical Co.,Ltd.

Entirely from the patients' perspective Providing dependable pharmaceuticals for the future of medicine Ohara Pharmaceutical Co.,Ltd.

September 13, 2017: A Cooperative Research Study with the National Cancer Center Japan (PDF: 1.03MB)
February 14, 2017: Postponement of the NHI Drug Price Listing and Launch of "ERWINASE^® for intramuscular injection 10000" (PDF: 129KB)
December 19, 2016: Acquisition of Marketing Approval in Japan for "ERWINASE^® for intramuscular injection 10000" (PDF: 168KB)
March 15, 2016: We presented company introduction including current market situation on Japan at The Orphan drugs & Rare Diseases Global Congress 2016 Europe. (PDF: 3.64MB)
December 17, 2015: Antineoplastic Enzyme Preparation "Crisantaspase" Submission of a Japan New Drug Application for the Treatment of Diseases including Acute Lymphocytic Leukemia and Malignant Lymphoma. (PDF: 110KB)